导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.16% | 867/4773 |
| 近一周 | 1.00% | 755/5467 |
| 近一月 | -8.21% | 3780/5421 |
| 近一季 | -2.03% | 1247/5238 |
| 近半年 | 10.24% | 671/4931 |
| 近一年 | 7.05% | 1337/4400 |
| 近两年 | 102.76% | 597/2954 |
| 近三年 | 66.44% | 380/2253 |
| 成立以来 | 84.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.54% 3859/4961 |
23.54% 1095/5312 |
- - |
- - |
| 2025 | 35.96% 964/4813 |
4.35% 952/3635 |
0.38% 2673/4076 |
41.34% 732/4524 |
-8.17% 3886/4813 |
| 2024 | 14.77% 1009/3463 |
-3.94% 1587/2808 |
-5.13% 1660/3014 |
18.23% 1039/3129 |
6.52% 507/3463 |
| 2023 | 2.91% 298/2656 |
24.92% 99/2280 |
-3.62% 845/2385 |
-12.04% 2102/2515 |
-2.83% 540/2655 |
| 2022 | -31.74% 1666/2207 |
-22.53% 1705/1919 |
1.46% 1475/2016 |
-17.05% 1545/2113 |
4.71% 517/2208 |
| 2021 | 10.00% 447/1822 |
-6.54% 1014/1255 |
12.42% 334/1330 |
-3.58% 647/1466 |
8.59% 147/1822 |
| 2020 | 40.96% 297/1250 |
3.49% 117/1028 |
25.42% 155/1067 |
2.22% 1008/1164 |
6.23% 764/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 富国中证科技50策略ETF VS. 长安沪深300非周期A(740101) |